Cargando…

A Novel Role for RARα Agonists as Apolipoprotein CIII Inhibitors Identified from High Throughput Screening

Elevated triglyceride (TG) levels are well-correlated with the risk for cardiovascular disease (CVD). Apolipoprotein CIII (ApoC-III) is a key regulator of plasma TG levels through regulation of lipolysis and lipid synthesis. To identify novel regulators of TG levels, we carried out a high throughput...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Sang Jun, Mahankali, Madhupriya, Bitar, Abdallah, Zou, Huafei, Chao, Elizabeth, Nguyen, Hung, Gonzalez, Jose, Caballero, Dawna, Hull, Mitch, Wang, Danling, Schultz, Peter G., Shen, Weijun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5517646/ https://www.ncbi.nlm.nih.gov/pubmed/28724938 http://dx.doi.org/10.1038/s41598-017-05163-w

Ejemplares similares

Elevated Levels of Apolipoprotein CIII Increase the Risk of Postprandial Hypertriglyceridemia
por: Guan, Yunpeng, et al.
Publicado: (2021)

Meal-Related Changes in Apolipoprotein Particles After Treatment With an Antisense Oligonucleotide to Apolipoprotein CIII
por: Brite, Brianna, et al.
Publicado: (2021)

Associations between apolipoprotein CIII concentrations and microalbuminuria in type 2 diabetes
por: HU, ZHI-JUAN, et al.
Publicado: (2014)

Effects of dietary saturated fat on LDL subclasses and apolipoprotein CIII in men
por: Faghihnia, Nastaran, et al.
Publicado: (2012)

Apolipoprotein CIII Is an Important Piece in the Type-1 Diabetes Jigsaw Puzzle
por: Valladolid-Acebes, Ismael, et al.
Publicado: (2021)

CD14(+)-Monocytes Exposed to Apolipoprotein CIII Express Tissue Factor
por: Olivieri, Oliviero, et al.
Publicado: (2023)

Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells
por: Sol, E-ri M, et al.
Publicado: (2009)

Large-Scale Analysis of Apolipoprotein CIII Glycosylation by Ultrahigh Resolution Mass Spectrometry
por: Demus, Daniel, et al.
Publicado: (2021)

Statins suppress apolipoprotein CIII-induced vascular endothelial cell activation and monocyte adhesion
por: Zheng, Chunyu, et al.
Publicado: (2013)

Apolipoprotein CIII may mediate the impacts of angiopoietin-like protein 8 on triglyceride metabolism
por: Luo, Mengdie, et al.
Publicado: (2018)

Lowering apolipoprotein CIII protects against high-fat diet–induced metabolic derangements
por: Valladolid-Acebes, Ismael, et al.
Publicado: (2021)

Apolipoprotein-CIII O-Glycosylation, a Link between GALNT2 and Plasma Lipids
por: Naber, Annemieke, et al.
Publicado: (2023)

Reversal by RARα agonist Am580 of c-Myc-induced imbalance in RARα/RARγ expression during MMTV-Myc tumorigenesis
por: Bosch, Almudena, et al.
Publicado: (2012)

Recent advances in the design of RAR α and RAR β agonists as orally bioavailable drugs. A review
por: Borthwick, Alan D., et al.
Publicado: (2020)

Apolipoprotein CIII Overexpressing Mice Are Predisposed to Diet-Induced Hepatic Steatosis and Hepatic Insulin Resistance
por: Lee, Hui-Young, et al.
Publicado: (2011)

The relationship between apolipoprotein CIII gene polymorphism and serum lipid levels in Han Chinese males()
por: Su, Shu, et al.
Publicado: (2013)

Why Is Apolipoprotein CIII Emerging as a Novel Therapeutic Target to Reduce the Burden of Cardiovascular Disease?
por: Taskinen, Marja-Riitta, et al.
Publicado: (2016)

Mass Spectrometry of Transferrin and Apolipoprotein CIII from Dried Blood Spots for Congenital Disorders of Glycosylation
por: Wada, Yoshinao, et al.
Publicado: (2022)

SstI Polymorphism of the Apolipoprotein CIII Gene in Iranian Hyperlipidemic Patients: A Study in Semnan Province
por: Bandegi, Ahmad Reza, et al.
Publicado: (2011)

Association of serum lipids and coronary artery disease with polymorphisms in the apolipoprotein AI-CIII-AIV gene cluster
por: Rai, Himanshu, et al.
Publicado: (2016)

Apolipoprotein CIII predicts cardiovascular events in patients with coronary artery disease: a prospective observational study
por: Katzmann, Julius L., et al.
Publicado: (2020)

Volanesorsen, an Antisense Oligonucleotide to Apolipoprotein-CIII, Decreases Triglycerides and Increases Lipoprotein Lipase Activity in Partial Lipodystrophy
por: Lightbourne, Marissa, et al.
Publicado: (2021)

Apolipoprotein CIII Overexpression-Induced Hypertriglyceridemia Increases Nonalcoholic Fatty Liver Disease in Association with Inflammation and Cell Death
por: Paiva, Adriene A., et al.
Publicado: (2017)

Apolipoprotein CIII Reduction Protects White Adipose Tissues against Obesity-Induced Inflammation and Insulin Resistance in Mice
por: Recio-López, Patricia, et al.
Publicado: (2021)

Apolipoprotein CIII regulates lipoprotein-associated phospholipase A(2) expression via the MAPK and NFκB pathways
por: Han, Xiaolei, et al.
Publicado: (2015)

Factor II Activity is Similarly Increased in Patients With Elevated Apolipoprotein CIII and in Carriers of the Factor II 20210A Allele
por: Olivieri, Oliviero, et al.
Publicado: (2013)

APOE genotype influences insulin resistance, apolipoprotein CII and CIII according to plasma fatty acid profile in the Metabolic Syndrome
por: Fallaize, Rosalind, et al.
Publicado: (2017)

Not Just Arterial Damage: Increased Incidence of Venous Thromboembolic Events in Cardiovascular Patients With Elevated Plasma Levels of Apolipoprotein CIII
por: Olivieri, Oliviero, et al.
Publicado: (2019)

Electrospray Ionization Mass Spectrometry of Apolipoprotein CIII to Evaluate O-glycan Site Occupancy and Sialylation in Congenital Disorders of Glycosylation
por: Wada, Yoshinao, et al.
Publicado: (2022)

Understanding the Action of RARγ Agonists on Human Osteochondroma Explants
por: Garcia, Sonia A., et al.
Publicado: (2020)

Plasma Apolipoprotein CI and CIII Levels Are Associated With Increased Plasma Triglyceride Levels and Decreased Fat Mass in Men With the Metabolic Syndrome
por: van der Ham, Rachel L.M., et al.
Publicado: (2009)

Mixed phenotype acute leukemia with PML-RARα positive: a case report and literature review
por: Zheng, Xiaolong, et al.
Publicado: (2021)

Apolipoprotein CIII overexpression exacerbates diet-induced obesity due to adipose tissue higher exogenous lipid uptake and retention and lower lipolysis rates
por: Raposo, Helena F., et al.
Publicado: (2015)

Is apoCIII-Lowering A Double-Edged Sword?
por: Tang, Xiangming, et al.
Publicado: (2022)

Identification of the HDL-ApoCIII to VLDL-ApoCIII ratio as a predictor of coronary artery disease in the general population: The Chin-Shan Community Cardiovascular Cohort (CCCC) study in Taiwan
por: Chang, Po-Yuan, et al.
Publicado: (2012)

Amplified Inhibition of Stellate Cell Activation Pathways by PPAR-γ, RAR and RXR Agonists
por: Sharvit, Efrat, et al.
Publicado: (2013)

Is RARS-T a new disease entity or a subtype of RARS or ET?
por: Bang, Soo-Mee
Publicado: (2010)

Regulation of RXR-RAR Heterodimers by RXR- and RAR-Specific Ligands and Their Combinations
por: le Maire, Albane, et al.
Publicado: (2019)

Conditional RARα knockout mice reveal acute requirement for retinoic acid and RARα in homeostatic plasticity
por: Sarti, Federica, et al.
Publicado: (2012)

Targeting RARA overexpression with tamibarotene, a potent and selective RARα agonist, is a novel approach in AML
por: de Botton, Stéphane, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0510opuonk6ave9muvu7r4pk26